87 related articles for article (PubMed ID: 8070291)
1. [The changes in copper contents and its clinical significance in patients with liver cirrhosis and hepatocarcinoma].
Zhang YJ; Zhao DH; Huang CX
Zhonghua Nei Ke Za Zhi; 1994 Feb; 33(2):113-6. PubMed ID: 8070291
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical characteristics of hepatocellular carcinoma in non-cirrhotic livers.
Witjes CD; ten Kate FJ; Verhoef C; de Man RA; IJzermans JN
J Clin Pathol; 2013 Aug; 66(8):687-91. PubMed ID: 23585667
[TBL] [Abstract][Full Text] [Related]
4. Des-gamma-carboxyprothrombin in patients with hepatocellular carcinoma and liver cirrhosis.
Inagaki Y; Xu HL; Hasegawa K; Aoki T; Beck Y; Sugawara Y; Tang W; Kokudo N
J Dig Dis; 2011 Dec; 12(6):481-8. PubMed ID: 22118699
[TBL] [Abstract][Full Text] [Related]
5. Iron, copper and zinc levels in serum and cirrhotic liver of patients with and without hepatocellular carcinoma.
Nagasue N; Kolno H; Chang YC; Nakamura T
Oncology; 1989; 46(5):293-6. PubMed ID: 2550861
[TBL] [Abstract][Full Text] [Related]
6. Copper levels in patients with rheumatoid arthritis.
Strecker D; Mierzecki A; Radomska K
Ann Agric Environ Med; 2013; 20(2):312-6. PubMed ID: 23772583
[TBL] [Abstract][Full Text] [Related]
7. Angiopoietin-2 serum levels are elevated in patients with liver cirrhosis and hepatocellular carcinoma.
Scholz A; Rehm VA; Rieke S; Derkow K; Schulz P; Neumann K; Koch I; Pascu M; Wiedenmann B; Berg T; Schott E
Am J Gastroenterol; 2007 Nov; 102(11):2471-81. PubMed ID: 17581268
[TBL] [Abstract][Full Text] [Related]
8. Application of HBx-induced anti-URGs as early warning biomarker of cirrhosis and HCC.
Wang W; Zhao LJ; Wang Y; Tao QY; Feitelson MA; Zhao P; Ren H; Qi ZT
Cancer Biomark; 2011-2012; 11(1):29-39. PubMed ID: 22820138
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor-II is a useful marker to detect hepatocellular carcinoma?
Morace C; Cucunato M; Bellerone R; De Caro G; Crinò S; Fortiguerra A; Spadaro F; Zirilli A; Alibrandi A; Consolo P; Luigiano C; Resta ML; Ferraù O; Spadaro A
Eur J Intern Med; 2012 Sep; 23(6):e157-61. PubMed ID: 22863442
[TBL] [Abstract][Full Text] [Related]
10. Increased levels of typically fetal bile acid species in patients with hepatocellular carcinoma.
El-Mir MY; Badia MD; Luengo N; Monte MJ; Marin JJ
Clin Sci (Lond); 2001 May; 100(5):499-508. PubMed ID: 11294690
[TBL] [Abstract][Full Text] [Related]
11. [Detection and evaluation of serum GP73, a resident Golgi glycoprotein, as a marker in diagnosis of hepatocellular carcinoma].
Zhao XY; Li N; Ding HG; Jiang FF
Zhonghua Zhong Liu Za Zhi; 2010 Dec; 32(12):943-5. PubMed ID: 21223806
[TBL] [Abstract][Full Text] [Related]
12. Relevance of non-ceruloplasmin copper to oxidative stress in patients with hepatocellular carcinoma.
Geetha A; Saranya P; Annie Jeyachristy S; Surendran R; Sundaram A
Biol Trace Elem Res; 2009 Sep; 130(3):229-40. PubMed ID: 19229483
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of the copper/zinc ratio in hepatocellular carcinoma: a case control study.
Poo JL; Rosas-Romero R; Montemayor AC; Isoard F; Uribe M
J Gastroenterol; 2003; 38(1):45-51. PubMed ID: 12560921
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of circulating activin-A as a serum marker of hepatocellular carcinoma.
Pirisi M; Fabris C; Luisi S; Santuz M; Toniutto P; Vitulli D; Federico E; Del Forno M; Mattiuzzo M; Branca B; Petraglia F
Cancer Detect Prev; 2000; 24(2):150-5. PubMed ID: 10917135
[TBL] [Abstract][Full Text] [Related]
15. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry.
Wang B; Chen D; Chen Y; Hu Z; Cao M; Xie Q; Chen Y; Xu J; Zheng S; Li L
J Proteome Res; 2012 Feb; 11(2):1217-27. PubMed ID: 22200553
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor beta1 and soluble Fas serum levels in hepatocellular carcinoma.
Sacco R; Leuci D; Tortorella C; Fiore G; Marinosci F; Schiraldi O; Antonaci S
Cytokine; 2000 Jun; 12(6):811-4. PubMed ID: 10843770
[TBL] [Abstract][Full Text] [Related]
17. [Zn. Cu and Fe changes in the serum and liver tissue in patients with liver cancer or post-hepatitic cirrhosis].
Zhang Z
Zhonghua Yi Xue Za Zhi; 1990 Sep; 70(9):512-4. PubMed ID: 1964856
[No Abstract] [Full Text] [Related]
18. [Application of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma].
Jia HL; Xing XJ; Ye QH; Qin LX
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):440-3. PubMed ID: 18795617
[TBL] [Abstract][Full Text] [Related]
19. [Study on the prognostic value of hepatocyte growth factor and c-met for patients with hepatocellular carcinoma].
Wu FS; Zheng SS; Wu LJ; Ding W; Ma ZM; Wang ZM; Teng LS; Zhao WH
Zhonghua Wai Ke Za Zhi; 2006 May; 44(9):603-8. PubMed ID: 16784653
[TBL] [Abstract][Full Text] [Related]
20. Combined serum hepatoma-specific alpha-fetoprotein and circulating alpha-fetoprotein-mRNA in diagnosis of hepatocellular carcinoma.
Wu W; Yao DF; Yuan YM; Fan JW; Lu XF; Li XH; Qiu LW; Zong L; Wu XH
Hepatobiliary Pancreat Dis Int; 2006 Nov; 5(4):538-44. PubMed ID: 17085339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
